Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
national blog main
national top stories
18
×
life sciences
biotech
boston blog main
boston top stories
san francisco blog main
san francisco top stories
boston
clinical trials
new york blog main
fda
startups
new york top stories
san diego blog main
deals
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
gene therapy
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san francisco
wisconsin blog main
wisconsin top stories
bristol-myers squibb
crispr
crispr therapeutics
europe blog main
gene editing
What
therapeutics
18
×
drug
medicines
million
new
gene
medicine
startup
ago
approval
cancer
crispr
fda
ipo
latest
nasdaq
raised
therapy
treat
years
adding
based
bets
bio
biotech
biotechs
companies
data
digital
drugs
editing
field
focus
humans
immunotherapy
life
medical
momentum
morning
phase
Language
unset
Current search:
therapeutics
×
" national top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
In Landmark Gene-Editing Study, Sangamo Reports Little Benefit
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
Delivery Robots in Big D, Rodriguez Leaves the Station, & More TX Tech
@xconomy.com
5 years ago
TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M